Discontinued — last reported Q4 '25
Year-over-year, this metric declined by 100.0%, from $831.00M to $0.00. Over 4 years (FY 2022 to FY 2026), Business Sale Proceeds shows a downward trend with a -16.7% CAGR.
An increase signals portfolio optimization or a strategic pivot, while a lack of proceeds suggests a stable, long-term asset base.
This metric represents the cash inflows received from the divestiture or sale of business segments, product lines, or su...
Occurs sporadically; peers often divest legacy segments to focus on high-margin innovation areas like continuous glucose monitoring or diagnostics.
cf_proceeds_from_sale_of_business| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $432.25M | $432.25M | $432.25M | $1.25M | $1.25M | $1.25M | $1.25M | $17.75M | $17.75M | $17.75M | $17.75M | $0.00 | $158.00M | $0.00 | $115.00M | $831.00M | $0.00 | $0.00 | $0.00 | $0.00 |
| QoQ Change | — | +0.0% | +0.0% | -99.7% | +0.0% | +0.0% | +0.0% | >999% | +0.0% | +0.0% | +0.0% | -100.0% | — | -100.0% | — | +622.6% | -100.0% | — | — | — |
| YoY Change | — | — | — | — | -99.7% | -99.7% | -99.7% | >999% | >999% | >999% | >999% | -100.0% | +790.1% | -100.0% | +547.9% | — | -100.0% | — | -100.0% | -100.0% |